It has been just over a month since the National Service Framework application for an NZ CAR-T service was submitted and endorsed by Leukaemia & Blood Cancer New Zealand (LBC).
CAR T-cell therapies are licensed for certain lymphomas, myeloma and B-cell leukaemias for routine use in other parts of the world, and LBC wants to see this in New Zealand. Having a national service framework for a CAR T-cell service is a small but critical step in the journey towards creating this new and innovative service – we want to see these steps quicken and continue!
What is CAR T-cell treatment? CAR T-cell therapy stands for Chimeric Antigen Receptor T-cell therapy and works by redirecting a patient’s own immune cells to target cancer cells. For more information visit the Malaghan Institute’s site https://www.malaghan.org.nz/our-research/car-t-cell/.
The wheels of government do not move with haste, but by coordinating key ‘voices’, we hope to build momentum and maintain the progress of this application. We are pleased to have these voices behind this, including: